ADXS11-001 immunotherapy targeting HPV-E7: Updated survival and safety data from a

Phase 2 study in Indian women with recurrent cervical cancer

Robert Petit1 and Partha Basu2

1Advaxis, Inc. Princeton, NJ 2Chittaranjan National Cancer Institute, Kolkata, India

Abstract

Life Cycle of Lm in APC

Lm-LLO Immunotherapy Safety: Frequency of SAEs in 110 patient Phase 2: ADXS11-001 vs. Chemotherapy

Overall Survival

Lm-LLO-E7-15 Best Response Data

ConclusionsCase Study: Patient 110-002

Landmark Survival Duration of Response (PFS)

Overall Survival: Aggressive vs. Non-

Aggressive Disease

Response by Aggressiveness of Disease &

Treatment Group

Lm-LLO-E7-015: A Randomized Phase 2 Study to Assess the Safety & Efficacy of

ADXS-HPV +/- cisplatin Treatment for Recurrent Cervical Cancer

Trial Design: Lm-LLO-E7-15

Safety